Nama's AI scorecard currently rates Certara Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CERT's P/E ratio?

Certara trades at a trailing price-to-earnings ratio of 34.4.

When does CERT report earnings?

Certara's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.09.

What is the CERT price target?

The median analyst price target from 11 analysts is $9.00, with a range of $7.00 – $12.00.

Is CERT Shariah compliant?

Nama's AAOIFI-style screen reads Certara as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Certara (CERT)

Healthcare · Health Information Services · NASDAQ

Certara (CERT) is a Healthcare company in the Health Information Services industry. It has a market capitalization of $1.84B, a trailing price-to-earnings ratio of 34.4 and a free-cash-flow yield of 3.6%. Over the most recent reported fiscal year, revenue grew 8.8% and free cash flow per share grew 17.4%. Nama's AI scorecard rates it Sell, 4.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 4.0/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · -20.5% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-72.5%

How far the last close sits under the highest price of the past five years.

Market cap	$1.84B
Trailing P/E	34.4
Price / book	1.9
Price / sales	4.4
FCF yield	3.6%
Dividend yield	—
Gross margin	61.9%
Operating margin	-0.2%
Net margin	-16.8%
Revenue growth (YoY)	+8.8%
Revenue growth (3-yr annual)	+7.7%
EPS growth (YoY)	-2.2%
FCF/share growth (YoY)	+17.4%
Beta	1.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Health Information Services

CERT earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.09). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.09	$0.09	+0.0%	$94.90M
Q2 2026	Aug 4, 2026	$0.08	$0.09	-11.1%	$93.27M
Q1 2026	May 11, 2026	$0.09	$0.11	-18.2%	$106.92M
Q4 2025	Feb 26, 2026	$0.09	$0.10	-10.0%	$103.65M

CERT analyst price target

Median target $9.00 from 11 analysts, ranging $7.00 – $12.00.

Health Information Services peers

Ticker	Company	Market cap	P/E
VEEV	Veeva Systems	$49.18B	35.0
TEM	Tempus AI	$13.87B	—
BTSG	BrightSpring Health Services	$13.36B	39.3
HNGE	Hinge Health	$9.34B	51.7
HQY	HealthEquity	$8.57B	23.3
TXG	10x Genomics	$7.72B	296.4
DOCS	Doximity	$5.79B	23.7
WAY	Waystar	$5.45B	17.2

Explore live CERT data on Nama Insights →

CERT FAQ

Is CERT a buy?: Nama's AI scorecard currently rates Certara Sell (4.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CERT's P/E ratio?: Certara trades at a trailing price-to-earnings ratio of 34.4.
When does CERT report earnings?: Certara's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.09.
What is the CERT price target?: The median analyst price target from 11 analysts is $9.00, with a range of $7.00 – $12.00.
Is CERT Shariah compliant?: Nama's AAOIFI-style screen reads Certara as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.